The University of Chicago Header Logo

Connection

Richard Schilsky to United States Food and Drug Administration

This is a "connection" page, showing publications Richard Schilsky has written about United States Food and Drug Administration.
  1. Access versus evidence: The regulators' dilemma. Clin Trials. 2018 06; 15(3):240-242.
    View in: PubMed
    Score: 0.154
  2. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
    View in: PubMed
    Score: 0.154
  3. Hans Christian Andersen and the Value of New Cancer Treatments. J Natl Cancer Inst. 2018 05 01; 110(5):441-442.
    View in: PubMed
    Score: 0.154
  4. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res. 2013 Jun 01; 19(11):2804-9.
    View in: PubMed
    Score: 0.108
  5. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14.
    View in: PubMed
    Score: 0.098
  6. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
    View in: PubMed
    Score: 0.093
  7. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91.
    View in: PubMed
    Score: 0.086
  8. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30.
    View in: PubMed
    Score: 0.083
  9. Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res. 2007 May 01; 13(9):2533-4.
    View in: PubMed
    Score: 0.072
  10. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol. 2003 Oct 15; 21(20):3718-20.
    View in: PubMed
    Score: 0.056
  11. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8.
    View in: PubMed
    Score: 0.050
  12. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411.
    View in: PubMed
    Score: 0.043
  13. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.032
  14. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
    View in: PubMed
    Score: 0.031
  15. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.